journal article·2023-10-25Open access

CO2-Driven Nebulization of pH-Sensitive Supramolecular Polymers for Intraperitoneal Hydrogel Formation and the Treatment of Peritoneal Metastasis

Helena Braet, Peter-Paul Fransen, Remco Mariën, Giovanna Lollo, Wim Ceelen, Chris Vervaet, Lieve Balcaen, Frank Vanhaecke, Christian Vanhove, Stefan van der Vegte, Elke Gasthuys, An Vermeulen, Patricia Y.W. Dankers, Stefaan C. De Smedt, Katrien Remaut

ACS Applied Materials & Interfaces· Volume 15· Issue 42

Abstract

Because peritoneal metastasis (PM) from ovarian cancer is characterized by non-specific symptoms, it is often diagnosed at advanced stages. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) can be considered a promising drug delivery method for unresectable PM. Currently, the efficacy of intraperitoneal (IP) drug delivery is limited by the off-label use of IV chemotherapeutic solutions, which are rapidly cleared from the IP cavity. Hence, this research aimed to improve PM treatment by evaluating a nanoparticle-loaded, pH-switchable supramolecular polymer hydrogel as a controlled release drug delivery system that can be IP nebulized. Moreover, a multidirectional nozzle was developed to allow nebulization of viscous materials such as hydrogels and to reach an even IP gel deposition. We demonstrated that acidification of the nebulized hydrogelator solution by carbon dioxide, used to inflate the IP cavity during laparoscopic surgery, stimulated the in situ gelation, which prolonged the IP hydrogel retention. In vitro experiments indicated that paclitaxel nanocrystals were gradually released from the hydrogel depot formed, which sustained the cytotoxicity of the formulation for 10 days. Finally, after aerosolization of this material in a xenograft model of PM, tumor progression could successfully be delayed, while the overall survival time was significantly increased compared to non-treated animals.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Intraperitoneal and Appendiceal Malignancies · Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, Ghent University, Ghent 9000, Belgium

CRIG − Cancer Research Institute Ghent, Ghent 9000, Belgium

UPyTher BV, Eindhoven 5600 MB, The Netherlands

Laboratoire d’Automatique, de Génie des Procédés et de Génie Pharmaceutique (LAGEPP), Université Claude Bernard Lyon 1, Lyon 69622, France

Department of Human Structure and Repair, Ghent University, Ghent 9000, Belgium

Department of Chemistry, Ghent University, Ghent 9000, Belgium

Department of Electronics and Information Systems, Ghent University, Ghent 9000, Belgium

Medspray b.v., Enschede 7521 PV, The Netherlands

Department of Bioanalysis, Ghent University, Ghent 9000, Belgium

Department of Biomedical Engineering and Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven 5600 MB, The Netherlands

Funding

Universiteit Gent · Fonds Wetenschappelijk Onderzoek · H2020 Health

References (70)

Show source-provided references
1. 10.1369/002215541774289710.1369/0022155417742897 ↗
2. 10.1016/S0140-6736(18)32552-210.1016/S0140-6736(18)32552-2 ↗
3. Ovarian Cancer Survival Rates | Ovarian Cancer Prognosis. American Cancer Society. https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html (accessed 2022-03-03).
4. 10.3322/caac.2010710.3322/caac.20107 ↗
5. 10.3322/caac.2166010.3322/caac.21660 ↗
6. 10.1016/j.ijpharm.2020.12004110.1016/j.ijpharm.2020.120041 ↗
7. 10.21037/JGO-2020-0610.21037/JGO-2020-06 ↗
8. 10.1002/bjs.1052110.1002/bjs.10521 ↗
9. 10.1080/17425247.2020.173655110.1080/17425247.2020.1736551 ↗
10. 10.1007/s00404-018-4784-710.1007/s00404-018-4784-7 ↗
11. 10.1016/S1470-2045(19)30318-310.1016/S1470-2045(19)30318-3 ↗
12. 10.21037/jgo-20-49710.21037/jgo-20-497 ↗
13. 10.1016/j.addr.2020.10.01510.1016/j.addr.2020.10.015 ↗
14. 10.1515/pp-2016-000510.1515/pp-2016-0005 ↗
15. 10.1038/s41598-019-51419-y10.1038/s41598-019-51419-y ↗
16. 10.1155/2013/72085810.1155/2013/720858 ↗
17. 10.1002/adhm.20200065510.1002/adhm.202000655 ↗
18. 10.1021/acsami.0c0555410.1021/acsami.0c05554 ↗
19. 10.1002/mabi.20170002410.1002/mabi.201700024 ↗
20. 10.1515/pp-2018-011210.1515/pp-2018-0112 ↗
21. 10.18632/oncotarget.2059610.18632/oncotarget.20596 ↗
22. Van Oudheusden T. R. · Anticancer Res. · 2015 · 35 · 627
23. 10.1016/j.surg.2013.04.05410.1016/j.surg.2013.04.054 ↗
24. 10.1080/21691401.2019.157670510.1080/21691401.2019.1576705 ↗
25. 10.1007/978-981-10-7053-2_2010.1007/978-981-10-7053-2_20 ↗
26. 10.1016/j.ejpb.2021.10.00110.1016/j.ejpb.2021.10.001 ↗
27. 10.12691/JPBPC-2-2-210.12691/JPBPC-2-2-2 ↗
28. 10.1002/advs.20170084810.1002/advs.201700848 ↗
29. 10.1038/s41565-018-0319-410.1038/s41565-018-0319-4 ↗
30. 10.1016/j.actbio.2019.03.03610.1016/j.actbio.2019.03.036 ↗
31. 10.1016/j.ejpb.2019.06.01510.1016/j.ejpb.2019.06.015 ↗
32. 10.1016/j.ejps.2017.06.02910.1016/j.ejps.2017.06.029 ↗
33. 10.1016/j.biomaterials.2018.04.05710.1016/j.biomaterials.2018.04.057 ↗
34. 10.1016/j.ijbiomac.2019.07.12610.1016/j.ijbiomac.2019.07.126 ↗
35. 10.1007/s00464-016-5174-510.1007/s00464-016-5174-5 ↗
36. 10.1016/j.jconrel.2023.08.04210.1016/j.jconrel.2023.08.042 ↗
37. 10.1002/adma.20110407210.1002/adma.201104072 ↗
38. 10.1002/adhm.20130007610.1002/adhm.201300076 ↗
39. 10.1089/lap.2006.16.65410.1089/lap.2006.16.654 ↗
40. 10.1007/s00464-007-9409-310.1007/s00464-007-9409-3 ↗
41. 10.3762/bjnano.8.27210.3762/bjnano.8.272 ↗
42. Lefebvre A. H. · 201710.1201/9781315120911 ↗
43. 10.1002/asia.20180058210.1002/asia.201800582 ↗
44. 10.1186/s12885-019-5658-510.1186/s12885-019-5658-5 ↗
45. 10.1038/nmeth.201910.1038/nmeth.2019 ↗
46. 10.1007/s11095-012-0765-x10.1007/s11095-012-0765-x ↗
47. 10.1016/j.jconrel.2019.10.05110.1016/j.jconrel.2019.10.051 ↗
48. 10.1016/j.ebiom.2022.10415110.1016/j.ebiom.2022.104151 ↗
49. 10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-U10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-U ↗
50. 10.1186/1471-2407-7-10410.1186/1471-2407-7-104 ↗
51. 10.1038/s41572-021-00326-610.1038/s41572-021-00326-6 ↗
52. 10.3390/cancers1203063310.3390/cancers12030633 ↗
53. 10.21873/anticanres.1261310.21873/anticanres.12613 ↗
54. 10.7150/jca.3909710.7150/jca.39097 ↗
55. 10.1590/s0102-86502017012000000710.1590/s0102-865020170120000007 ↗
56. 10.1007/s00464-004-2214-310.1007/s00464-004-2214-3 ↗
57. 10.1007/s00268-015-2973-010.1007/s00268-015-2973-0 ↗
58. 10.1016/j.jclinane.2013.07.01310.1016/j.jclinane.2013.07.013 ↗
59. 10.4097/kja.d.18.0029010.4097/kja.d.18.00290 ↗
60. 10.1016/j.ejso.2021.12.31910.1016/j.ejso.2021.12.319 ↗
61. 10.1016/j.ejso.2021.12.31810.1016/j.ejso.2021.12.318 ↗
62. 10.1039/C6PY01101B10.1039/C6PY01101B ↗
63. 10.1021/jp409936v10.1021/jp409936v ↗
64. 10.1021/acsami.7b1199810.1021/acsami.7b11998 ↗
65. 10.1016/S1470-2045(03)01074-X10.1016/S1470-2045(03)01074-X ↗
66. 10.1201/b1940910.1201/b19409 ↗
67. 10.1016/j.jconrel.2011.12.00110.1016/j.jconrel.2011.12.001 ↗
68. 10.1016/j.jconrel.2016.05.05610.1016/j.jconrel.2016.05.056 ↗
69. 10.1002/adhm.20200134110.1002/adhm.202001341 ↗
70. 10.3390/gels602001410.3390/gels6020014 ↗